Merck Wins $2.5 Billion from Gilead Over Hepatitis C Drug Patent

A gastroenterologist sheds light on Crohn’s
December 22, 2016
Hope Lights the Way to a Cure for MS
December 23, 2016
Show all

Merck Wins $2.5 Billion from Gilead Over Hepatitis C Drug Patent

A lawsuit between hepatitis C manufacturers Merck and Gilead was recently concluded.

Merck on Thursday was awarded $2.54 billion in royalties by a federal jury in a patent lawsuit against Gilead GILD 0.40% over Gilead‘s blockbuster hepatitis C drugs Sovaldi and Harvoni.

The jury in Delaware reached the verdict following a nearly two-week trial, finding that a patent acquired by Merck in 2014 on hepatitis C treatments was valid.

“The jury’s verdict upholds patent protections that are essential to the development of new medical treatments,” Merck said in a statement Thursday.

Gilead spokeswoman Michele Rest said the company disagreed with the verdict and would appeal it. She said it did not stop Gilead from continuing to sell its drugs.

Merck’s stock rose slightly to $63 in late trade on the New York Stock Exchange. Gilead‘s shares fell 2 percent to $74.06 on the Nasdaq.

Read full article: Merck Wins $2.5 Billion from Gilead Over Hepatitis C Drug Patent

Read Full Article: Merck Wins $2.5 Billion from Gilead Over Hepatitis C Drug Patent

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.